Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumours

Trial Identifier:	D6015C00001
Sponsor:	AstraZeneca
NCTID::	NCT02482311
Start Date:	July 2015
Primary Completion Date:	January 2018
Study Completion Date:	August 2019
Condition:	Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Translation
	French Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203
US, TN	Nashville, TN, US, 37203

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company